Neurocrine Biosciences (NASDAQ:NBIX) Stock Gets Price Target Increase from Piper Sandler

Neurocrine Biosciences (NASDAQ:NBIX) had its price target hoisted by stock analysts at Piper Sandler from $210.00 to $215.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler‘s price objective indicates a potential upside of 47.92% from the company’s previous close.

A number of other research analysts have also commented on the stock. Wall Street Zen lowered shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Sunday, August 9th. UBS Group lowered their price objective on Neurocrine Biosciences from $231.00 to $214.00 and set a “buy” rating on the stock in a research report on Tuesday, September 29th. Wells Fargo & Company lifted their price objective on Neurocrine Biosciences from $175.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Canaccord Genuity Group boosted their target price on Neurocrine Biosciences from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Finally, Mizuho upgraded Neurocrine Biosciences to a “hold” rating in a research note on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $201.36.

Neurocrine Biosciences Trading Down 0.5%

NASDAQ:NBIX opened at $145.35 on Tuesday. Neurocrine Biosciences has a 12 month low of $122.14 and a 12 month high of $186.12. The firm’s 50 day moving average is $146.49 and its 200 day moving average is $147.45. The stock has a market capitalization of $14.77 billion, a PE ratio of 21.31, a price-to-earnings-growth ratio of 0.64 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Monday, November 2nd. The company reported $3.29 earnings per share for the quarter, topping the consensus estimate of $1.91 by $1.38. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter last year, the company earned $2.04 earnings per share. The company’s revenue was up 41.3% on a year-over-year basis. Research analysts predict that Neurocrine Biosciences will post 7.72 earnings per share for the current year.

Insider Activity

In related news, CFO Matt Abernethy sold 2,311 shares of the stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $157.20, for a total transaction of $363,289.20. Following the sale, the chief financial officer directly owned 42,808 shares of the company’s stock, valued at approximately $6,729,417.60. This represents a 5.12% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider David W. Boyer sold 826 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $157.45, for a total transaction of $130,053.70. Following the sale, the insider directly owned 8,722 shares of the company’s stock, valued at $1,373,278.90. This trade represents a 8.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in Neurocrine Biosciences in the second quarter valued at about $2,310,886,000. Bank of New York Mellon Corp purchased a new position in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $117,827,000. Ieq Capital LLC purchased a new position in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $107,914,000. Bank of America Corp DE acquired a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at approximately $104,382,000. Finally, Man Group plc purchased a new stake in shares of Neurocrine Biosciences in the second quarter valued at approximately $101,293,000. Institutional investors own 92.59% of the company’s stock.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Strong third-quarter results: Neurocrine reported adjusted earnings of $3.29 per share, up from $2.04 a year earlier and above consensus estimates ranging from $1.91 to $2.67. Revenue increased 41.3% year over year to approximately $1.12 billion, exceeding the roughly $1.04 billion estimate. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Product sales exceeded $1 billion for the first time: Management attributed the milestone to strong demand across its portfolio of medicines, indicating continued commercial momentum and a broader revenue base. Neurocrine Biosciences Crosses $1 Billion in Quarterly Product Sales
• Positive Sentiment: INGREZZA guidance raised: Neurocrine increased its 2026 net sales guidance for INGREZZA (valbenazine) to $2.9 billion-$2.925 billion. The upgraded outlook reinforces expectations for sustained demand for the company’s leading commercial product. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Neutral Sentiment: Management’s earnings-call presentations and transcripts provide additional detail on quarterly performance, product demand, and the company’s outlook. Investors will likely focus on whether the strong growth and raised guidance can continue into 2027. Neurocrine Q3 2026 Earnings Call Transcript

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.